IDO-IN-7 NEW
| Price | $38 | $68 | $117 |
| Package | 10mg | 25mg | 50mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-11-11 |
Product Details
| Product Name: IDO-IN-7 | CAS No.: 1402836-58-1 |
| Purity: 100.00% | Supply Ability: 10g |
| Release date: 2025/11/11 |
Product Introduction
Bioactivity
| Name | IDO-IN-7 |
| Description | IDO-IN-7 (NLG-919 analogue) is a potent inhibitor of the IDO (indoleamine-(2, 3)-dioxygenase) pathway. |
| In vitro | In mice bearing B16F10 tumors, NLG919 significantly enhanced the antitumor response of pmel-1 resting cells to homologous hgp100 peptide and CpG-1826. |
| In vivo | NLG919 effectively blocks the IDO-induced suppression of T-cell responses, restoring T-cell activity (ED50=80 nM). In mouse dendritic cells (DCs) expressing IDO from tumor lymph nodes (ED50=120 nM), NLG919 abolishes the IDO-induced inhibition of antigen-specific T-cells (OT-1). |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : 26 mg/mL (92.07 mM), Sonication is recommended. DMSO : 45 mg/mL (159.36 mM), Sonication is recommended. H2O : < 1 mg/mL (insoluble or slightly soluble) 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (7.08 mM), Sonication is recommended. |
| Keywords | NLG919 analogue | NLG-919 | NLG 919 | Navoximod analogue | Indoleamine2,3Dioxygenase(IDO) | Indoleamine2,3Dioxygenase | Indoleamine 2,3-Dioxygenase (IDO) | Indoleamine 2,3Dioxygenase (IDO) | Indoleamine 2,3-Dioxygenase | IDO-IN-7 | IDOIN7 | IDO IN 7 | IDO | GDC-0919 analogue | GDC0919 | GDC 0919 |
| Inhibitors Related | Palmatine chloride | GNF-PF-3777 | Coptisine chloride | Necrostatin-1 | Indoximod | Palmatine | IDO inhibitor 1 | Epacadostat | β-Lapachone | IDO5L | 3-TYP | IDO-IN-12 |
| Related Compound Libraries | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | ReFRAME Related Library | Anti-Cancer Metabolism Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Anti-Metabolism Disease Compound Library | Human Metabolite Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1820.00/25mg |
VIP4Y
|
TargetMol Chemicals Inc.
|
2025-07-19 | |
| $0.00/10mg |
VIP2Y
|
ShenZhen H&D Pharmaceutical Technology Co., LTD
|
2024-08-13 | |
| $5.00/5KG |
VIP8Y
|
Career Henan Chemical Co
|
2019-09-03 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY